Citations (74)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Kevin Rouault-Pierre, Ashley Hamilton & Dominique Bonnet. (2016) Effect of hypoxia-inducible factors in normal and leukemic stem cell regulation and their potential therapeutic impact. Expert Opinion on Biological Therapy 16:4, pages 463-476.
Read now
Read now
Moustapha Ouédraogo, Eve De Maesschalck, Valérie Soentjens-Werts & Jacques Dubois. (2009) In vitro cytotoxicity study of oxaziridines generated after chlordiazepoxide, demoxepam, and desmethylchlordiazepoxide UV irradiation. Drug and Chemical Toxicology 32:4, pages 417-423.
Read now
Read now
Girja S Shukla & David N Krag. (2006) Selective delivery of therapeutic agents for the diagnosis and treatment of cancer. Expert Opinion on Biological Therapy 6:1, pages 39-54.
Read now
Read now
William A Denny. (2005) Hypoxia-activated anticancer drugs. Expert Opinion on Therapeutic Patents 15:6, pages 635-646.
Read now
Read now
William A. Denny. (2004) Tumor-activated Prodrugs—A New Approach to Cancer Therapy. Cancer Investigation 22:4, pages 604-619.
Read now
Read now
Articles from other publishers (69)
Zhaoyu Han, Yue Qian, Xiyue Gao, Dutao Yang, Yanfei Cai, Yun Chen, Jian Jin & Zhaoqi Yang. (2023) Hypoxia-responsive covalent organic framework by single NIR laser-triggered for multimodal synergistic therapy of triple-negative breast cancer. Colloids and Surfaces B: Biointerfaces 222, pages 113094.
Crossref
Crossref
Longshuai Zhang, Jiawei Sun, Wenchao Huang, Sanke Zhang, Xuliang Deng & Weiping Gao. (2023)
Hypoxia-Triggered Bioreduction of Poly(
N
-oxide)–Drug Conjugates Enhances Tumor Penetration and Antitumor Efficacy
. Journal of the American Chemical Society 145:3, pages 1707-1713.
Crossref
Crossref
Paul J. Smith, Stephanie R. McKeown & Laurence H. Patterson. (2022)
Targeting
DNA
topoisomerase
IIα
(
TOP2A
) in the hypoxic tumour microenvironment using unidirectional hypoxia‐activated prodrugs (
uHAPs
)
. IUBMB Life 75:1, pages 40-54.
Crossref
Crossref
Yifei Xia, Shao Duan, Chaozhe Han, Chengwei Jing, Zunyu Xiao & Chao Li. (2022) Hypoxia-responsive nanomaterials for tumor imaging and therapy. Frontiers in Oncology 12.
Crossref
Crossref
Agata Krzak, Olga Swiech, Maciej Majdecki, Piotr Garbacz, Paulina Gwardys & Renata Bilewicz. (2021) Adjusting the Structure of β-Cyclodextrin to Improve Complexation of Anthraquinone-Derived Drugs. Molecules 26:23, pages 7205.
Crossref
Crossref
Haohao Yin, Bangguo Zhou, Chongke Zhao, Liping Sun, Wenwen Yue, Xiaolong Li, Hongyan Li, Shaoyue Li, Huixiong Xu & Yu Chen. (2021) 2D Core/Shell‐Structured Mesoporous Silicene@Silica for Targeted and Synergistic NIR‐II‐Induced Photothermal Ablation and Hypoxia‐Activated Chemotherapy of Tumors. Advanced Functional Materials 31:24, pages 2102043.
Crossref
Crossref
Donald J. AbrahamDeepak K. Dalvie & Bernard Testa. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
139
.
Slobodan P. Rendic & F. Peter Guengerich. (2021) Human Family 1–4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update. Archives of Toxicology 95:2, pages 395-472.
Crossref
Crossref
Rishabh Kaushik, Sheeza Khan, Meesha Sharma, Srinivasan Hemalatha, Zeba Mueed & Nitesh K. Poddar. (2020) Role of Cytochrome P450 in Prostate Cancer and its Therapy. Current Enzyme Inhibition 16:1, pages 63-73.
Crossref
Crossref
Mengbi Yang, Jiang Ma, Jianqing Ruan, Yang Ye, Peter Pi-Cheng Fu & Ge Lin. (2019) Intestinal and hepatic biotransformation of pyrrolizidine alkaloid N-oxides to toxic pyrrolizidine alkaloids. Archives of Toxicology 93:8, pages 2197-2209.
Crossref
Crossref
Julia K. Harms, Tet-Woo Lee, Tao Wang, Amy Lai, Dennis Kee, John M. Chaplin, Nick P. McIvor, Francis W. Hunter, Andrew M. J. Macann, William R. Wilson & Stephen M.F. Jamieson. (2019) Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models. Cells 8:7, pages 717.
Crossref
Crossref
Josh W. DiGiacomo & Daniele M. Gilkes. 2019. Hypoxia and Cancer Metastasis. Hypoxia and Cancer Metastasis
141
157
.
Hui-Li Xu, Jian-Bo Cheng, Hai-Bei Li, Xin Yang & Qing-Zhong Li. (2018)
Tetrel bonds between PhSiF
3
/PhTH
3
(T = Si, Ge, Sn) and H
3
ZO (Z = N, P, As): A pentacoordinate silicon (IV) complex
. International Journal of Quantum Chemistry 118:17, pages e25660.
Crossref
Crossref
Paul J. Smith, Zbigniew Darzynkiewicz & Rachel J. Errington. (2018) Nuclear cytometry and chromatin organization. Cytometry Part A 93:8, pages 771-784.
Crossref
Crossref
Xin Luan, Ying-Yun Guan, Hai-Jun Liu, Qin Lu, Mei Zhao, Duxin Sun, Jonathan F. Lovell, Peng Sun, Hong-Zhuan Chen & Chao Fang. (2018) A Tumor Vascular-Targeted Interlocking Trimodal Nanosystem That Induces and Exploits Hypoxia. Advanced Science 5:8, pages 1800034.
Crossref
Crossref
Heather Nesbitt, Jenny Worthington, Rachel J. Errington, Laurence H. Patterson, Paul J. Smith, Stephanie R. McKeown & Declan J. McKenna. (2017) The unidirectional hypoxia-activated prodrug OCT1002 inhibits growth and vascular development in castrate-resistant prostate tumors. The Prostate 77:15, pages 1539-1547.
Crossref
Crossref
Mikhail A. Syroeshkin, Igor B. Krylov, Audrey M. Hughes, Igor V. Alabugin, Darya V. Nasybullina, Mikhail Yu. Sharipov, Vadim P. Gultyai & Alexander O. Terent'ev. (2017)
Electrochemical behavior of
N
-oxyphthalimides: Cascades initiating self-sustaining catalytic reductive
N
―
O
bond cleavage
. Journal of Physical Organic Chemistry 30:9, pages e3744.
Crossref
Crossref
Heather Nesbitt, Niall M. Byrne, S. Nicole Williams, Louise Ming, Jenny Worthington, Rachel J. Errington, Laurence H. Patterson, Paul J. Smith, Stephanie R. McKeown & Declan J. McKenna. (2017) Targeting Hypoxic Prostate Tumors Using the Novel Hypoxia-Activated Prodrug OCT1002 Inhibits Expression of Genes Associated with Malignant Progression. Clinical Cancer Research 23:7, pages 1797-1808.
Crossref
Crossref
Ronaldo Custodio de Souza Oliveira, Rodrigo José Corrêa, Raquel Simas Pereira Teixeira, Daniela Dias Queiroz, Rodrigo da Silva Souza, Simon John Garden, Nanci Camara de Lucas, Marcos Dias Pereira, Josué Sebastián Bello Forero, Eric Cardona Romani & Emerson Schwingel Ribeiro. (2016) Silica nanoparticles doped with anthraquinone for lung cancer phototherapy. Journal of Photochemistry and Photobiology B: Biology 165, pages 1-9.
Crossref
Crossref
Zonghua Wang, Zhengxiao Liu, Lili Li & Qionglin Liang. (2015) Investigation into the hypoxia-dependent cytotoxicity of anticancer drugs under oxygen gradient in a microfluidic device. Microfluidics and Nanofluidics 19:6, pages 1271-1279.
Crossref
Crossref
Carmen Avendaño & J. Carlos Menéndez. 2015. Medicinal Chemistry of Anticancer Drugs. Medicinal Chemistry of Anticancer Drugs
595
653
.
Thorsten H. Ecke. 2015. Advances in Cancer Biomarkers. Advances in Cancer Biomarkers
293
316
.
Juliana Benito, Marina Konopleva & William R. Wilson. 2015. Targeted Therapy of Acute Myeloid Leukemia. Targeted Therapy of Acute Myeloid Leukemia
657
679
.
Barbara MuzPilar de la PuenteFeda AzabMicah LudererAbdel Kareem Azab. (2014) The Role of Hypoxia and Exploitation of the Hypoxic Environment in Hematologic Malignancies. Molecular Cancer Research 12:10, pages 1347-1354.
Crossref
Crossref
Jingli Wang, Chris P. Guise, Gabi U. Dachs, Yen Phung, Annie (Huai-Ling) Hsu, Neil K. Lambie, Adam V. Patterson & William R. Wilson. (2014) Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5. Biochemical Pharmacology 91:4, pages 436-446.
Crossref
Crossref
William R. Wilson, Kevin O. Hicks, Jingli Wang & Frederik B. Pruijn. 2014. Hypoxia and Cancer. Hypoxia and Cancer
283
328
.
Yafei Li, Ning Zhao, Zhenling Zeng, Xiaoyan Gu, Binghu Fang, Fan Yang, Bingxu Zhang & Huanzhong Ding. (2013) Tissue Deposition and Residue Depletion of Cyadox and Its Three Major Metabolites in Pigs after Oral Administration. Journal of Agricultural and Food Chemistry 61:39, pages 9510-9515.
Crossref
Crossref
Juliana Benito, Zhihong Zeng, Marina KonoplevaWilliam R Wilson. (2013) Targeting hypoxia in the leukemia microenvironment. International Journal of Hematologic Oncology 2:4, pages 279-288.
Crossref
Crossref
Paul R Ortiz de Montellano. (2013) Cytochrome P450-activated prodrugs. Future Medicinal Chemistry 5:2, pages 213-228.
Crossref
Crossref
Eugene ManleyJr.Jr. & David J. Waxman. (2013) Impact of Tumor Blood Flow Modulation on Tumor Sensitivity to the Bioreductive Drug Banoxantrone. Journal of Pharmacology and Experimental Therapeutics 344:2, pages 368-377.
Crossref
Crossref
T C Jackson, J D Verrier & P M Kochanek. (2013) Anthraquinone-2-sulfonic acid (AQ2S) is A Novel Neurotherapeutic Agent. Cell Death & Disease 4:1, pages e451-e451.
Crossref
Crossref
Angela Alama, Anna Maria Orengo, Silvano Ferrini & Rosaria Gangemi. (2012) Targeting cancer-initiating cell drug-resistance: a roadmap to a new-generation of cancer therapies?. Drug Discovery Today 17:9-10, pages 435-442.
Crossref
Crossref
Aude Carreau, Bouchra El Hafny-Rahbi, Agata Matejuk, Catherine Grillon & Claudine Kieda. (2011) Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia. Journal of Cellular and Molecular Medicine 15:6, pages 1239-1253.
Crossref
Crossref
Paul J. Smith, Roy Edward & Rachel J. Errington. 2010. Flow Cytometry in Drug Discovery and Development. Flow Cytometry in Drug Discovery and Development
23
54
.
Jennifer M. Atkinson, Robert A. Falconer, Dylan R. Edwards, Caroline J. Pennington, Catherine S. Siller, Steven D. Shnyder, Michael C. Bibby, Laurence H. Patterson, Paul M. Loadman & Jason H. Gill. (2010) Development of a Novel Tumor-Targeted Vascular Disrupting Agent Activated by Membrane-Type Matrix Metalloproteinases. Cancer Research 70:17, pages 6902-6912.
Crossref
Crossref
Clinton R. Nishida, Melody Lee & Paul R. Ortiz de Montellano. (2010) Efficient Hypoxic Activation of the Anticancer Agent AQ4N by CYP2S1 and CYP2W1. Molecular Pharmacology 78:3, pages 497-502.
Crossref
Crossref
Kaye J. Williams, Mark R. Albertella, Brian Fitzpatrick, Paul M. Loadman, Steven D. Shnyder, Edwin C. Chinje, Brian A. Telfer, Chris R. Dunk, Peter A. Harris & Ian J. Stratford. (2009)
In vivo
activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts
. Molecular Cancer Therapeutics 8:12, pages 3266-3275.
Crossref
Crossref
Moana Tercel, Graham J. Atwell, Shangjin Yang, Ralph J. Stevenson, K. Jane Botting, Maruta Boyd, Eileen Smith, Robert F. Anderson, William A. Denny, William R. Wilson & Frederik B. Pruijn. (2009)
Hypoxia-Activated Prodrugs: Substituent Effects on the Properties of Nitro
seco
-1,2,9,9a-Tetrahydrocyclopropa[
c
]benz[
e
]indol-4-one (nitroCBI) Prodrugs of DNA Minor Groove Alkylating Agents
. Journal of Medicinal Chemistry 52:22, pages 7258-7272.
Crossref
Crossref
Jared B. J. Milbank, Ralph J. Stevenson, David C. Ware, John Y. C. Chang, Moana Tercel, G-One Ahn, William R. Wilson & William A. Denny. (2009)
Synthesis and Evaluation of Stable Bidentate Transition Metal Complexes of 1-(Chloromethyl)-5-hydroxy-3-(5,6,7-trimethoxyindol-2-ylcarbonyl)-2,3-dihydro-1
H
-pyrrolo[3,2-
f
]quinoline (
seco
-6-azaCBI-TMI) as Hypoxia Selective Cytotoxins
. Journal of Medicinal Chemistry 52:21, pages 6822-6834.
Crossref
Crossref
Peter Hlavica. (2009) Assembly of non-natural electron transfer conduits in the cytochrome P450 system: A critical assessment and update of artificial redox constructs amenable to exploitation in biotechnological areas. Biotechnology Advances 27:2, pages 103-121.
Crossref
Crossref
Olivier Trédan, Alaina B. Garbens, Alshad S. Lalani & Ian F. Tannock. (2009) The Hypoxia-Activated ProDrug AQ4N Penetrates Deeply in Tumor Tissues and Complements the Limited Distribution of Mitoxantrone. Cancer Research 69:3, pages 940-947.
Crossref
Crossref
Yu Chen & Longqin Hu. (2008) Design of anticancer prodrugs for reductive activation. Medicinal Research Reviews 29:1, pages 29-64.
Crossref
Crossref
Kyriakos P. Papadopoulos, Sanjay Goel, Murali Beeram, Alvin Wong, Kavita Desai, Missak Haigentz, María L. Milián, Sridhar Mani, Anthony Tolcher, Alshad S. Lalani & John Sarantopoulos. (2008) A Phase 1 Open-Label, Accelerated Dose-Escalation Study of the Hypoxia-Activated Prodrug AQ4N in Patients with Advanced Malignancies. Clinical Cancer Research 14:21, pages 7110-7115.
Crossref
Crossref
María Laura Lavaggi, Mauricio Cabrera, Mercedes González & Hugo Cerecetto. (2008) Differential Enzymatic Reductions Governing the Differential Hypoxia-Selective Cytotoxicities of Phenazine 5,10-Dioxides. Chemical Research in Toxicology 21:9, pages 1900-1906.
Crossref
Crossref
Clinton R. Nishida & Paul R. Ortiz de Montellano. (2008)
Reductive Heme-Dependent Activation of the
N
-Oxide Prodrug AQ4N by Nitric Oxide Synthase
. Journal of Medicinal Chemistry 51:16, pages 5118-5120.
Crossref
Crossref
Tim IllidgeSrinivasan Madhusudan, Daniel Patterson & Adrian Harris. 2008. Treatment of Cancer Fifth Edition. Treatment of Cancer Fifth Edition
251
268
.
J.K. Adamski, E.J. Estlin & G.W.J. Makin. (2008) The cellular adaptations to hypoxia as novel therapeutic targets in childhood cancer. Cancer Treatment Reviews 34:3, pages 231-246.
Crossref
Crossref
Qi-Biao Su, Fan He, Xue-Ding Wang, Su Guan, Zhi-Yong Xie, Lai-You Wang, Yu-Jing Lu, Lian-Quan Gu, Zhi-Shu Huang, Xiao Chen, Min Huang & Shu-Feng Zhou. (2007) Biotransformation and pharmacokinetics of the novel anticancer drug, SYUIQ-5, in the rat. Investigational New Drugs 26:2, pages 119-137.
Crossref
Crossref
Mark R. Albertella, Paul M. Loadman, Philip H. Jones, Roger M. Phillips, Roy Rampling, Neil Burnet, Chris Alcock, Alan Anthoney, Egils Vjaters, Chris R. Dunk, Peter A. Harris, Alvin Wong, Alshad S. Lalani & Chris J. Twelves. (2008) Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study. Clinical Cancer Research 14:4, pages 1096-1104.
Crossref
Crossref
Carmen Avendaño & J. Carlos Menéndez. 2008. Medicinal Chemistry of Anticancer Drugs. Medicinal Chemistry of Anticancer Drugs
351
385
.
Ricky A. Sharma, Katherine A. Vallis & W. Gillies McKenna. 2008. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
417
448
.
Julia A. Barnett, Diana L. Urbauer, Graeme I. Murray, Gregory N. Fuller & Amy B. Heimberger. (2007)
Cytochrome
P
450 1B1 Expression in Glial Cell Tumors: An Immunotherapeutic Target
. Clinical Cancer Research 13:12, pages 3559-3567.
Crossref
Crossref
William R. Wilson, Kevin O. Hicks, Susan M. Pullen, Dianne M. Ferry, Nuala A. Helsby & Adam V. Patterson. (2007) Bystander Effects of Bioreductive Drugs: Potential for Exploiting Pathological Tumor Hypoxia with Dinitrobenzamide Mustards. Radiation Research 167:6, pages 625-636.
Crossref
Crossref
Steven X. Hu, Richard Soll, Shiyin Yee, Daniel L. Lohse, Ahmed Kousba, Binqi Zeng, Xiyun Yu, Andrew McPherson, Joel Renick, Jianguo Cao, Arek Tabak, John Hood, John Doukas, Glenn Noronha & Michael Martin. (2007)
Metabolism and Pharmacokinetics of a Novel Src Kinase Inhibitor TG100435 ([7-(2,6-Dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine) and Its Active
N
-Oxide Metabolite TG100855 ([7-(2,6-Dichloro-phenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-{4-[2-(1-oxy-pyrrolidin-1-yl)-ethoxy]-phenyl}-amine)
. Drug Metabolism and Disposition 35:6, pages 929-936.
Crossref
Crossref
Alshad S. Lalani, Susan E. Alters, Alvin Wong, Mark R. Albertella, Jeffrey L. Cleland & William David Henner. (2007) Selective Tumor Targeting by the Hypoxia-Activated Prodrug AQ4N Blocks Tumor Growth and Metastasis in Preclinical Models of Pancreatic Cancer. Clinical Cancer Research 13:7, pages 2216-2225.
Crossref
Crossref
J. Martin Brown. 2007. Oxygen Biology and Hypoxia. Oxygen Biology and Hypoxia
295
321
.
W.F. Trager. 2007. Comprehensive Medicinal Chemistry II. Comprehensive Medicinal Chemistry II
87
132
.
Klaus Pors, Steven D. Shnyder, Paul H. Teesdale-Spittle, John A. Hartley, Mire Zloh, Mark Searcey & Laurence H. Patterson. (2006)
Synthesis of DNA-Directed Pyrrolidinyl and Piperidinyl Confined Alkylating Chloroalkylaminoanthraquinones: Potential for Development of Tumor-Selective
N
-Oxides
. Journal of Medicinal Chemistry 49:24, pages 7013-7023.
Crossref
Crossref
G-One Ahn, K. Jane Botting, Adam V. Patterson, David C. Ware, Moana Tercel & William R. Wilson. (2006) Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator. Biochemical Pharmacology 71:12, pages 1683-1694.
Crossref
Crossref
Abby Rosenberg & Susan Knox. (2006) Radiation sensitization with redox modulators: A promising approach. International Journal of Radiation Oncology*Biology*Physics 64:2, pages 343-354.
Crossref
Crossref
Sarah Jane Lunt & Richard P. Hill. 2006. Cancer Drug Resistance. Cancer Drug Resistance
43
66
.
Diane Downie, Morag C.E. McFadyen, Patrick H. Rooney, Margaret E. Cruickshank, David E. Parkin, Iain D. Miller, Colin Telfer, William T. Melvin & Graeme I. Murray. (2005)
Profiling Cytochrome
P
450 Expression in Ovarian Cancer: Identification of Prognostic Markers
. Clinical Cancer Research 11:20, pages 7369-7375.
Crossref
Crossref
Meera Kumarakulasingham, Patrick H. Rooney, Sinclair R. Dundas, Colin Telfer, William T. Melvin, Stephanie Curran & Graeme I. Murray. (2005) Cytochrome P450 Profile of Colorectal Cancer: Identification of Markers of Prognosis. Clinical Cancer Research 11:10, pages 3758-3765.
Crossref
Crossref
Hsu-Shan Huang, Hui-Fen Chiu, Wei-Chih Lu & Chun-Lung Yuan. (2005) Synthesis and Antitumor Activity of 1,8-Diaminoanthraquinone Derivatives. CHEMICAL & PHARMACEUTICAL BULLETIN 53:9, pages 1136-1139.
Crossref
Crossref
John R Cashman. (2004) The implications of polymorphisms in mammalian flavin-containing monooxygenases in drug discovery and development. Drug Discovery Today 9:13, pages 574-581.
Crossref
Crossref
J. Martin Brown & William R. Wilson. (2004) Exploiting tumour hypoxia in cancer treatment. Nature Reviews Cancer 4:6, pages 437-447.
Crossref
Crossref
Morag C. E. McFadyen, William T. Melvin & Graeme I. Murray. (2004)
Cytochrome
P
450 enzymes: Novel options for cancer therapeutics
. Molecular Cancer Therapeutics 3:3, pages 363-371.
Crossref
Crossref
William A. Denny. (2004) The Design of Drugs that Target Tumour Hypoxia. Australian Journal of Chemistry 57:9, pages 821.
Crossref
Crossref
Bernd Clement & Katrin Lopian. (2003) Characterization of in Vitro Biotransformation of New, Orally Active, Direct Thrombin Inhibitor Ximelagatran, an Amidoxime and Ester Prodrug. Drug Metabolism and Disposition 31:5, pages 645-651.
Crossref
Crossref